论文信息 - Healthcare Cost Impact of Continued Anticoagulation with Rivaroxaban versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the EINSTEIN-CHOICE Trial Population Continued Anticoagulation with Rivaroxaban for Prevention of Recurrent Symptomatic Venous Thromboembolism in - 字舞流文

Healthcare Cost Impact of Continued Anticoagulation with Rivaroxaban versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the EINSTEIN-CHOICE Trial Population Continued Anticoagulation with Rivaroxaban for Prevention of Recurrent Symptomatic Venous Thromboembolism in

M. Prins | Yongling Xiao | P. Prandoni | P. Wells | B. Levitan | P. Lefebvre | F. Laliberté | C. Crivera | J. Beyer-Westendorf | L. Haskell | Zhong Yuan | V. Ashton | Qi Zhao | D. Lejeune | Jeff | Anthonie WA. | Lensing | D. R. Schein | J. Beyer-Westendorf | Patrick Lefebvre | Philip S. Wells | P. Prandoni | Martin H. Prins | Lloyd Haskell | Yongling Xiao | Qi Zhao | Zhong Yuan | Jeff